Dr. Hanid Audish

Dr. Hanid Audish and the team at Encompass Clinical Research have begun phase two of their newest study evaluating the efficacy and safety of CIN-107, a hypertension medication. This study will assess the effects of three oral doses of CIN-107 versus a placebo pill over the course of twelve weeks. CIN-107 is a new medication designed for patients with treatment-resistant hypertension who are unable to control their blood pressure levels. Hanid Audish MD and the Encompass team are currently recruiting test subjects for the study that meet specific criteria.One of the biggest challenges for people with hypertension and other cardiovascular diseases is maintaining their goal blood pressure levels. This is especially difficult for those with treatment-resistant form of hypertension. Resistant hypertension, or RHTN, is defined as uncontrolled blood pressure despite the use of >3 anti-hypertensive agents of different classes, one of which must be a diuretic,…at maximally tolerated doses. Those with RHTN normally have 130/80mmHG, although this number depends on the individual. For those with hypertension, an RHTN diagnosis is especially concerning as it increases the likelihood of heart attack, kidney failure, and stroke.The CIN-107 study will be the first of its kind, as the study drug is a new medication within a new class of medications. The study will be a “randomized, double-blind, placebo-controlled, dose-ranging Phase 2” study and will comprise of men and women with a seated BP of more than 130/80mmHg. The study members must be on a stable regimen of more than three anti-hypertensive agents (one of which is a diuretic) for four weeks prior to the study and have complied with at least 70% of their anti-hypertensive medication regimen.The CIN-107 study is financed by the pharmaceutical company CinCor. CinCor is a clinical-stage biopharmaceutical company based in the Midwest. The CinCor company focuses on primarily cardiovascular, metabolic, and kidney disease medication. CIN-107, their newest lead program, is regarded as highly innovative based on its novel aldosterone synthase inhibitor. Aldosterone is an essential hormone in the adrenal gland that regulates salt and water in the body, thus greatly affecting blood pressure. CinCor and the Encompass Clinical Research team believe that CIN-107 testing should conclude by early 2021.